<DOC>
	<DOCNO>NCT00649051</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Mylan metolazone 2.5 mg tablet Celltech Zaroxolyn® 2.5 mg tablet follow single , oral 10 mg ( 4 x 2.5 mg ) dose administration fasting condition .</brief_summary>
	<brief_title>Fasting Study Metolazone Tablets 2.5 mg Zaroloxyn® Tablets 2.5 mg</brief_title>
	<detailed_description />
	<mesh_term>Metolazone</mesh_term>
	<criteria>1 . Age : 18 year old 2 . Sex : Male and/or nonpregnant , nonlactating female 1 . Women childbearing potential must negative serum ( βHCG ) pregnancy test perform within 14 day prior start study within 72 hour prior start dose treatment period . An additional serum ( βHCG ) pregnancy test perform upon completion study . 2 . Women childbearing potential must practice abstinence use acceptable form contraception throughout duration study . Acceptable form contraception include follow : 1. intrauterine device place least 3 month prior start study remain place study period , 2. barrier method contain use conjunction spermicidal agent , 3. surgical sterility ( tubal ligation , oophorectomy hysterectomy ) postmenopausal accompany postmenopausal course least one year , document subject 's medical history . 3 . During course study , study screen study exit include washout period , male must use spermicidecontaining barrier method contraception prevent pregnancy sexual partner . This advice document informed consent form . 3 . Weight : At least 60 kg ( 132 lb . ) men 48 kg ( 106 lb . ) woman within 15 % Ideal Body Weight ( IBW ) , reference Table `` Desirable Weights Adults '' Metropolitan Life Insurance Company , 1999 ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 4 . All subject judge normal healthy prestudy medical evaluation ( physical examination , laboratory evaluation , 12lead ECG , Hepatitis B , Hepatitis C HIV test , urine drug screen include amphetamine , benzodiazepine , cannabinoid , cocaine , opiate screen , phencyclidine ) perform within 14 day initial dose study medication . 1 . Institutionalized subject use . 2 . Social Habits : 1 . Use tobacco product within one year prior dose . 2 . Ingestion alcoholic , caffeine xanthinecontaining food beverage within 48 hour prior initial dose study medication . 3 . Ingestion vitamins herbal product within 48 hour prior initial dose study medication . 4 . Any recent , significant change dietary exercise habit . 3 . Medications : 1 . Use medication within last 14 day prior initial dose study medication , include use oral contraceptive , hormone replacement therapy , overthecounter medication . 2 . Use medication know alter hepatic enzyme activity within 28 day prior initial dose study medication . 4 . Diseases : 1 . History significant chronic disease and/or hepatitis . 2 . History drug and/or alcohol abuse . 3 . Acute illness time either prestudy medical evaluation dosing . 4 . A positive HIV , Hepatitis B , Hepatitis C test result . 5 . Abnormal clinically significant laboratory test result : 1 . Clinically significant deviation Guide Clinically Relevant Abnormalities ( See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS ) . 2 . Abnormal clinically relevant ECG tracing . 6 . Donation loss significant volume blood plasma ( &gt; 450 mL ) within 28 day prior initial dose study medication . 7 . Subjects receive investigational drug within 30 day prior initial dose study medication . 8 . Allergy hypersensitivity metolazone , sulfonamidederived drug , thiazide , quinethazone related product . 9 . History difficulty swallow , gastrointestinal disease could affect drug absorption . 10 . Consumption grapefruit grapefruit containing product within 48 hour drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>